Pharmacodynamic study of the Saltz regimen for metastatic colorectal cancer in a hemodialyzed patient

Chemotherapy

Volumn 53, Issue 6, 2007, Pages 418-421

  Akiyama, Shinichiro ^a,b,d   Nakayama, Hidetsugu ^c   Takami, Hiroya ^a   Gotoh, Hiromichi ^b   Gotoh, Yoshikazu ^b  

^a Saiyu Kawaguchi Clinic   (Japan)

^b Saiyu Soka Hospital   (Japan)

^c TSUKUBA MEDICAL CENTER HOSPITAL   (Japan)

^d Saiyu Kawaguchi Clinic   (Japan)

Author keywords

5 Fluorouracil; Colorectal carcinoma; Hemodialysis; Irinotecan; l Leucovorin; Pharmacokinetics; Saltz regimen

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN;

AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CANCER THERAPY; CASE REPORT; COLORECTAL CANCER; DISEASE SEVERITY; DRUG METABOLISM; HEMODIALYSIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FUNCTION; MALE; METASTASIS; PRIORITY JOURNAL; SIGMOIDECTOMY;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DIABETES MELLITUS, TYPE 1; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 36048942619     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000110006     Document Type: Article

References (14)

1. Robert F, Martinez-Maldonado M: Cancer in the renal failure patients; in Eknoyan G, Knochel JP (eds): The Systemic Consequences of Renal Failure. New York, Grune & Strattorn, 1985, pp 535-553.
2. Robles NR, Calero R, Rengel M, Valderrabano F: Hemodialysis and cancer. Nephron 1990;54:271-272.
3. Ito T, Tanaka I, Kadoya T, Kimura M, Ooshiro T, Ooishi K, Tanaka J, Yorioka N: Screening for gastroenterological malignancies in new and maintenance dialysis patients. J Gastroenterol 1999;34:35-40.
4. Piedbois P, Buyse M, Rustun Y, Machover D, Erlichman C, Carlson RW, Valone F, Labianca R, Doroshow JH, Petrelli N: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 1992;10:896-903.
5. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-914.
6. Heggie GD, Sommadossi JP, Cross DS, Haster WJ, Diasio RB: Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 1987;47:2203-2206.
7. Stemmler J, Weise A, Hacker U, Heinemann V, Schalhorn A: Weekly irinotecan in a patient with metastatic colorectal cancer on hemodialysis due to chronic renal failure. Onkologie 2002;25:60-63.
8. Sai K, Kaniwa N, Ozawa S, Sawada J: An analytical method for irinotecan (CPT-11) and its metabolites using a high-performance liquid chromatography: parallel detection with fluorescence and mass spectrometry. Biomed Chromatogr 2002;16:209-218.
9. Masuike T, Watanabe I, Takemoto Y: Quantitative method of 5-fluorouracil and its metabolites in biological samples using high performance liquid chromatography. Yakugaku Zasshi 1985;105:1058-1064.
10. Taguchi T, Wakui A, Hasegawa K, Niitani H, Furue H, Ohta K, Hattori T: Phase I clinical study of CPT-11. Research group of CPT-11. Gan To Kagaku Ryoho 1990;17:115-120.
11. Rengelshausen J, Hull WE, Schwenger V, Goggelmann C, Walter-Sack I, Bommer J: Pharmacokinetics of 5-fluorouracil and its catabolites determined by 19F nuclear magnetic resonance spectroscopy for a patient on chronic hemodialysis. Am J Kidney Dis 2002;39:E10.
12. Dohden K, Ohmura K, Watanabe Y: Ternary complex formation and reduced folate in surgical specimens of human adenocarcinoma tissues. Cancer 1993;71:471-480.
13. Tsavaris NB, Polyzos A, Gennatas K, Kosmas C, Vadiaka M, Dimitrakopoulos A, Macheras A, Papastratis G, Tsipras H, Margaris H, Papalambros E, Giannopoulos A, Koufos C: Irinotecan (CPT-11) in patients with advanced colon carcinoma relapsing after 5-fluorouracil-leucovorin combination. Chemotherapy 2002;48:94-99.
14. Grivicich I, Regner A, da Rocha AB, Kayser GB, Schunemann DP, Grass LB, Alves PA, Henriques JA, Schwartsmann G: The irinotecan/ 5-fluorouracil combination induces apoptosis and enhances manganese superoxide dismutase activity in HT-29 human colon carcinoma cells. Chemotherapy 2005;51:93-102.